Evaluating the Effects of Oral and Topical Simvastatin in the Treatment of Acne Vulgaris: A Double-blind, Randomized, Placebo-controlled Clinical Trial [0.03%]
评估西立伐他汀口服和外用治疗寻常痤疮的疗效：一项双盲随机对照临床试验
Anahita Ahmadvand,Ameneh Yazdanfar,Fatemeh Yasrebifar et al.
Anahita Ahmadvand et al.
Background: Acne vulgaris is a common dermatologic disorder which results in psychological consequences. Inflammatory responses play an important role in the development of inflammatory acne lesions. Recently, many studie...
Randomized Controlled Trial
Current clinical pharmacology. 2018;13(4):279-283. DOI:10.2174/1574884713666180821143545 2018
Jaspreet Kaur Boparai,Surjit Singh,Priyanka Kathuria
Jaspreet Kaur Boparai
Background: A questionnaire is a commonly used data collection method and is a very crucial part of the research. However, designing a questionnaire can be a daunting task for postgraduate students. ...
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature [0.03%]
1型糖尿病 mellitus中 SGLT-2抑制剂的文献综述
Dimitrios Patoulias,Konstantinos Imprialos,Konstantinos Stavropoulos et al.
Dimitrios Patoulias et al.
Background: Sodium-Glucose Cotransporter 2 (SGTL-2) inhibitors are a new class of antidiabetics, which have been approved for the treatment of patients with Type 2 Diabetes Mellitus (T2DM). Besides their beneficial metabo...
A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer's Disease [0.03%]
ω-3脂肪酸对阿尔茨海默病的影响的最新研究进展
Thekkuttuparambil Ananthanarayanan Ajith
Thekkuttuparambil Ananthanarayanan Ajith
Dietary long chain polyunsaturated fatty acids belong to omega (ω)-3, -6 or -9 series. Both experimental and clinical studies demonstrated the beneficial effect of ω -3 fatty acids of fish oil, Eicosapentaenoic Acid (EPA) and Docosahexaen...
Paolo Usai-Satta,Massimo Bellini,Mariantonia Lai et al.
Paolo Usai-Satta et al.
Background: Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder. It is characterised by abdominal pain, bloating and changes in bowel habits that can have a serious impact ...
Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy [0.03%]
抗体药物偶联物：靶向抗癌治疗的顶点回顾
Mahmudul Hasan,Safaet Alam,Saikat Kumar Poddar
Mahmudul Hasan
Cancer is one of the deadly diseases which is characterized by unchecked cell division or abnormal cell growth due to the incapability of cell cycle arrest. As the treatment for this is to kill the cancerous cells, the main challenge for sc...
Differentially Enhancing Effects of Long-term Treatment with Serrazyme, Boswellia and Pine on Seminal Bacterial Detection in Patients with Chronic Bacterial or Inflammatory Prostatitis, Probably Related to Several Degrees of Bacterial Adherence [0.03%]
长期使用丝裂酶、乳香和松树对慢性细菌性或炎症性前列腺炎患者精液中细菌检出率的差异增强作用，可能与几个程度的细菌黏附有关
Enzo Vicari,Giulia Malaguarnera,Beatrice Ornella Vicari et al.
Enzo Vicari et al.
Background: Prostatitis is a recurrent urinary infection in males and is often difficult to cure. The aim of the study was to examine whether anti-inflammatory effects of enhanced drainage of prostatic secretions, obtaine...
Randomized Controlled Trial
Current clinical pharmacology. 2018;13(3):183-189. DOI:10.2174/1574884713666180803114654 2018
Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics [0.03%]
基于纳米载体的小干扰RNA(siRNA)药物传输的治疗作用：药基因组学的一个新的分子方法研究进展
Javad Akhtari,Alireza Tafazoli,Hassan Mehrad-Majd et al.
Javad Akhtari et al.
Background: RNA interference (RNAi) is a process for regulating the gene expression in which small interfering RNAs (siRNAs) silence target genes. siRNA-based therapy as a new molecular treatment approach, offers therapeu...
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy [0.03%]
新型免疫治疗时代的晚期非小细胞肺癌非致癌基因成瘾性二线治疗：新的治疗策略算法
Cesare Gridelli,Paolo Antonio Ascierto,Francesco Grossi et al.
Cesare Gridelli et al.
Background: Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several nov...
Ryuichi Sakate,Akiko Fukagawa,Yuri Takagaki et al.
Ryuichi Sakate et al.
Background: Drug development for rare diseases is challenging because it is difficult to obtain relevant data from very few patients. It must be informative to grasp current status of clinical trials for drug development ...
Comparative Study
Current clinical pharmacology. 2018;13(3):199-208. DOI:10.2174/1574884713666180604081349 2018